摘要
骨转移是恶性肿瘤常见的并发症.在发生骨转移的患者中,晚期乳腺癌和前列腺癌患者约占80%,肺癌、结肠癌、胃癌、膀胱癌、子宫癌、直肠癌、甲状腺癌和肾癌患者占15%-30%。全世界每年约有150万恶性肿瘤患者发生骨转移.因此对恶性肿瘤骨转移的治疗也越来越引起关注。
出处
《北京医学》
CAS
2010年第2期138-140,共3页
Beijing Medical Journal
参考文献14
-
1Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun,2005,328:746-750.
-
2Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metallopreteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology,2005,69:35-43.
-
3Clezardin P, Ebetino FH, Foumier PG.Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.Cancer Res,2005, 65:4971-4974.
-
4Tripathy D, Lichinitzer M, Lazarev A,et al.Oral ibandronate for the treatment of metastatic bone disease in breast cancer:, efficacy and safety results from a randomized,double-blind,placebo-controlled trial. Ann Oncol,2004, 15:743-750.
-
5Body JJ, Diel IJ, Bell R,et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain,2004,111:306-312.
-
6Heidenreich A, Ohlmarm C, Body JJ.Ibandronate in metastatic bone pain. Semin Oncol,2004,31:67-72.
-
7Pecherstorfer M.Efficacy and safety of ibandronate in the treatment of neoplastic bone disease. Expert Opin Pharmacother,2004,5:2341-2350.
-
8Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rew,2005, 3: 19-25.
-
9董梅,冯奉仪,张阳,谢广茹,王雅洁,刘基巍,宋三泰,周清华,任军,焦顺昌,李进,王秀问,陈强,王哲海,徐农,冯继峰.唑来膦酸治疗实体瘤骨转移或多发性骨髓瘤中重度骨痛的Ⅲ期临床研究[J].中华肿瘤杂志,2008,30(3):215-220. 被引量:20
-
10Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledrenic acid. J Clin Oncol,2005,23:4925-4935.
二级参考文献14
-
1Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res, 1995, 10:1478-1487.
-
2Rogers MJ, Chilton KM, Coxon FP, et al. Bisphosphonates induce apoptosis in mouse maerophage-like ceils in vitro by a nitric oxideindependent mechanism. J Bone Miner Res, 1996, 11: 1482-1491.
-
3Rosen LS, Cordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disadium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, 98 : 1735-1744.
-
4Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronie acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ, double-blind, randomized triM. J Clin Oncol, 2003, 21:3150-3157.
-
5Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002, 94 : 1458-1468.
-
6Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol, 2005, 23:3314-3321.
-
7Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer, 2000, 88:2919-2926.
-
8Lipton A, Costa L, Ali SM, et al. Bone markers in the management of metastatic bone disease. Cancer Treat Rev, 2001, 27 : 181-185.
-
9Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer, 2003, 89:2031-2037.
-
10Brown JE, Cook R J, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst, 2005, 97:59-69.
共引文献19
-
1应筱莉,陈旭烽,周月芬,王永辉.唑来膦酸治疗既往用过双膦酸盐的实体瘤骨痛的疗效观察[J].浙江临床医学,2008,10(12):1562-1564. 被引量:2
-
2应筱莉,陈旭烽,周月芬,王永辉.唑来膦酸治疗既往用过双膦酸盐的实体瘤骨转移患者骨痛的安全性分析[J].肿瘤学杂志,2008,14(12):1019-1021. 被引量:1
-
3王妹兴,戴月娣,陶莉,李安琪,江联萍,肖谜,杨梅.双膦酸盐治疗骨转移癌骨痛及对血清钙磷的影响[J].中国癌症杂志,2010,20(11):842-846. 被引量:7
-
4刘婷智,王艳玲,吴海鹰,周宁宁,高红飞,刘克军.骨标志物N—MID、β-CTX在晚期肺癌骨转移患者中临床意义[J].医学信息(下旬刊),2011,24(2):3-4. 被引量:4
-
5Yuedi Dai Meixing Wang Li Tao Anqi Li Haixia Wu Mi Xiao.双膦酸盐对骨转移癌骨痛治疗及血清钙磷影响(英文)[J].The Chinese-German Journal of Clinical Oncology,2011,10(6):344-348. 被引量:2
-
6邓文娟,肖伟.唑来膦酸治疗恶性肿瘤骨转移临床疗效评价[J].河南外科学杂志,2011,17(6):69-70. 被引量:2
-
7李绪渊,林英城,黄婉兰,王鸿彪,林雯,洪超群,陈炯玉.唑来膦酸对人鼻咽癌HNE1细胞的抗增殖和抗侵袭作用[J].中华医学杂志,2011,91(32):2278-2282. 被引量:1
-
8张明帅,张国庆,欧江华,艾司克尔.阿尤甫,蒋威华,倪多.唑来磷酸联合卡培他滨治疗乳腺癌多发骨转移临床疗效研究[J].中国全科医学,2011,14(35):4103-4105. 被引量:7
-
9邹国荣,曹小龙,李济时,张超,彭苗.唑来膦酸治疗肺癌骨转移患者首次骨相关事件的临床分析[J].中国医药,2012,7(6):730-732. 被引量:3
-
10漆兴芝,刘斐.卡培他滨联合唑来膦酸治疗乳腺癌多发骨转移的效果及安全性[J].中国医药指南,2012,10(32):217-218. 被引量:1
同被引文献31
-
1Paice JA, Ferrell B, The Management of Cancer Pain. CA Cancer J Clin, 2011, 61 : 157 - 182.
-
2Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res, 2006, 12 : 6243s - 6249s.
-
3Delaney A, Fleetwood-Walker SM, Colvin LA, et al. Translational medicine: cancer pain mechanisms and management. Br J Anaesth, 2008, 101 : 87-94.
-
4Suva L J, Washam C, Richard W, et al. Bone meta- stasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol, 2011, 7 : 208 - 218.
-
5Luger NM, Mach DB, Sevcik MA, et al. Bone canc- er pain: from model to mechanism to therapy J Pa- in symptom manage, 2005, 29 : S32 - S46.
-
6Rainsford KD. Anti-inflammatory drugs in the 21 st century. Subcell Biochem, 2007, 42 : 3 - 27.
-
7Saito O, Aoe T, Yamamoto T. Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminoph- en, and morphine in a mouse model of bone cancer pain. J Anesth, 2005, 19 : 218 - 224.
-
8McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev, 2005, 1 : 5180.
-
9King T, Vardanyan A, Majuta L, et al. Morphine treatment accelerates sarcoma-induc-ed bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain, 2007, 132 : 154 - 68.
-
10Costa L, Lipton A, Coleman RE. Role of Bisphosp- honates for the Mangement of Skeletal Complica- tions and Bone Pain from Skeletal metastases. Suppot Cancer Ther, 2006, 3 : 143 - 153.
二级引证文献25
-
1曹启旺,黄东,徐慧巧,吴礼平,谷思汉.普瑞巴林联合鞘内输注舒芬太尼治疗骨转移癌爆发痛的临床研究[J].中南大学学报(医学版),2014,39(4):384-388. 被引量:10
-
2吴秋兰.中药封包联合红外线治疗癌性骨痛疗效观察与护理[J].生物技术世界,2013,10(10). 被引量:1
-
3余桂英,侯明君.癌性骨痛患者的护理[J].解放军护理杂志,2013,30(1):48-49. 被引量:3
-
4史鹤玲,李雪冰,张同梅,胡范彬,吕嘉林,孟弃逸,李宝兰.癌痛患者疼痛门诊药物治疗的临床效果分析[J].中国肿瘤临床,2013,40(24):1506-1508. 被引量:28
-
5史鹤玲,李雪冰,张同梅,胡范彬,吕嘉林,孟弃逸,李宝兰.癌痛患者疼痛门诊药物治疗的临床效果分析[J].结核病与胸部肿瘤,2014(1):26-28.
-
6王双伟,司玉玲.帕米膦酸二钠联合复方苦参注射液治疗恶性肿瘤骨转移所致疼痛的疗效观察[J].现代药物与临床,2014,29(4):397-400. 被引量:14
-
7饶爱华,王燕山,许建新.外用癌痛消联合肿瘤深部热疗治疗急症骨转移癌爆发痛的临床研究[J].中国中医急症,2014,23(12):2192-2193. 被引量:3
-
8王明闯,张菲菲,王忠民.王忠民辨证治疗子宫肌腺病剧痛经验[J].中国中医急症,2014,23(12):2220-2222. 被引量:11
-
9曹小飞,刘国龙,陈小君,关明媚,吕琳,方喜生.局部姑息性放疗与口服阿片类药物治疗肿瘤骨转移疼痛的临床疗效比较[J].肿瘤药学,2016,6(3):189-192. 被引量:3
-
10虞晓林,申泓.唑来膦酸联合化疗治疗非小细胞肺癌骨转移的疗效观察[J].实用临床医药杂志,2016,20(11):156-158. 被引量:24
-
1梁鹏.骨转移瘤综合治疗[J].国际骨科学杂志,2008,29(6):366-369. 被引量:1
-
2马建华,郭嘉漪.三维适形放疗联合双膦酸盐治疗骨转移癌的临床观察[J].山西医科大学学报,2013,44(9):727-728. 被引量:3
-
3钟林,王冬.两种方案治疗56例宫颈癌骨转移的回顾性分析[J].中国药房,2015,26(26):3681-3683. 被引量:5
-
4董梅,陈学鹏,冯奉仪.双膦酸盐治疗恶性肿瘤骨转移的研究进展[J].中华肿瘤杂志,2007,29(11):801-803. 被引量:8
-
5杨辉,胡庆涛,段寄辉.早期应用双膦酸盐治疗乳腺癌骨转移的临床价值探析[J].当代医学,2016,22(12):8-9. 被引量:3
-
6蔡树华,张东成,桂东.立体定向放疗联合双膦酸盐治疗脊柱转移癌的近期临床疗效观察[J].颈腰痛杂志,2011,32(2):153-154.
-
7梁忠,李雨林,于珺.乳腺癌骨转移同位素与双膦酸盐治疗的对比研究[J].中国医师进修杂志,2008,31(2):17-19. 被引量:1
-
8邹炳文,宋海侠,张瑜,周麟,朱江,刘咏梅,黄媚娟,李潞,徐泳.帕米膦酸二钠和唑来膦酸治疗非小细胞肺癌骨转移疗效和安全性比较[J].华西医学,2011,26(2):212-215. 被引量:2
-
9郑建萍,陈静波,崔同建,刘振华,陈峥,张桂枫,李德育,戴永美.胃癌骨转移43例临床特点及预后因素分析[J].福建医药杂志,2017,39(2):43-45.
-
10董梅,冯奉仪.双膦酸盐治疗恶性肿瘤骨转移新进展[J].癌症进展,2008,6(1):6-10. 被引量:22